ETF Holdings Breakdown of EOLS

Stock NameEvolus Inc
TickerEOLS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS30052C1071
LEI549300VYQRYBQOT8V419

News associated with EOLS

Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Invesco Ltd.
Invesco Ltd. reduced its position in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 81.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 18,326 shares of the company’s stock after selling 83,072 shares during the quarter. Invesco Ltd.’s holdings in Evolus were worth $202,000 at the end of the most recent quarter. Other institutional investors […] - 2025-05-05 07:26:46
ExodusPoint Capital Management LP Purchases New Position in Evolus, Inc. (NASDAQ:EOLS)
ExodusPoint Capital Management LP acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 13,525 shares of the company’s stock, valued at approximately $149,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes […] - 2025-04-15 07:38:57
KLP Kapitalforvaltning AS Invests $106,000 in Evolus, Inc. (NASDAQ:EOLS)
KLP Kapitalforvaltning AS bought a new position in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor bought 9,600 shares of the company’s stock, valued at approximately $106,000. Several other large investors have also recently added to or reduced their […] - 2025-04-11 08:14:55
Evolus, Inc. (NASDAQ:EOLS) Position Boosted by Intech Investment Management LLC
Intech Investment Management LLC raised its holdings in shares of Evolus, Inc. (NASDAQ:EOLS – Free Report) by 32.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,674 shares of the company’s stock after acquiring an additional 4,613 shares during the period. […] - 2025-03-27 08:29:02
HC Wainwright Reaffirms “Buy” Rating for Evolus (NASDAQ:EOLS)
Evolus (NASDAQ:EOLS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $27.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 100.00% from the stock’s current price. Several […] - 2025-03-07 06:50:44
China Universal Asset Management Co. Ltd. Acquires 1,291 Shares of Evolus, Inc. (NASDAQ:EOLS)
China Universal Asset Management Co. Ltd. grew its holdings in Evolus, Inc. (NASDAQ:EOLS – Free Report) by 10.6% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 13,426 shares of the company’s stock after acquiring an additional 1,291 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Evolus were worth $148,000 […] - 2025-02-04 08:53:02

EOLS institutional holdings

The following institutional investment holdings of EOLS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 42,938USD 433,244
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 12,739USD 128,537
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 30,082USD 303,527
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 30,082USD 303,527 -16.6%
Total =115,841 USD 1,168,835
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.